Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 22, 2026

4 Medical Supply Stocks Poised to Gain in a Prospering Industry

View original at finance.yahoo.com
4 Medical Supply Stocks Poised to Gain in a Prospering Industry The Zacks Medical - Dental Supplies industry in the Medical sector is likely to continue its upward momentum in 2026, backed by persistent innovation, an aging population with increasing healthcare needs and normalized orders following significant destocki…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cardinal Health expects revenues from its Pharmaceutical segment to grow 15-17% year over year in fiscal 2026

    80% confidence
  • Align Technology views DSOs as a 'force multiplier' and expects them to remain a high-growth segment into 2026

    80% confidence
  • The Zacks Medical Dental Supplies industry is likely to continue its upward momentum in 2026

    80% confidence
  • Align Technology's restructuring actions are expected to lift operating margins by at least 100 basis points year over year in 2026

    80% confidence
  • The global medical supplies industry is expected to reach $163.5 billion by 2027, at a CAGR of 3.4% in the 2022-2027 period

    80% confidence
  • West Pharmaceutical aims for organic revenue growth of 7-9% over the long-term

    80% confidence
  • McKesson expects total revenues to grow 11-15% and operating profit to improve 12-16% in fiscal 2026

    80% confidence
  • A significant contract manufacturing agreement is set to expire in mid-2026, representing a $40 million headwind in the second half of 2026

    80% confidence
  • Cardinal Health expects adjusted EPS to be at least $10.00 for fiscal 2026

    80% confidence
  • Cardinal Health expects revenues from the Medical segment to grow 2-4% in fiscal 2026

    80% confidence
  • Cardinal Health expects revenues from the Other segment to grow 26-28% in fiscal 2026

    80% confidence
  • The rise of oral GLP-1 therapies increases the risk of future market share shifts from injectables, which could potentially pressure the top line

    80% confidence
  • The U.S. had 55.8 million people aged 65 and above in 2020

    80% confidence
  • Advanced robotics and automated storage and retrieval systems are transforming logistics, cutting human intervention by nearly 75% for some companies

    80% confidence
  • Although the company plans to mitigate tariff-related costs in 2026, they are likely to hurt margins this year

    80% confidence
  • DSOs have demonstrated an ability to grow at double-digit rates, even in mixed economic environments

    80% confidence
  • ClinCheck Live Plan can automate treatment plans in as little as 15 minutes

    80% confidence
  • McKesson expects fiscal 2026 earnings per share to be in the range of $38.35-$38.85

    80% confidence
  • Management indicated that the company intends to operate within its long-term model of 5-15% growth

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
4 Medical Supply Stocks Poised to Gain in a Prospering Industry — Source | Via News | Via News